## Ozgur Ozyilkan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1833003/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2019, 393, 1819-1830.	6.3	2,347
2	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 1915-1928.	6.3	1,804
3	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
4	ESMO takes a stand on supportive and palliative care. Annals of Oncology, 2003, 14, 1335-1337.	0.6	99
5	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of Oncology, 2019, 30, 766-773.	0.6	78
6	A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit. Oral Oncology, 2012, 48, e2-e3.	0.8	37
7	Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer, 2011, 71, 109-112.	0.9	29
8	Signet-ring cell carcinoma of the gallbladder: a case report. Advances in Therapy, 2008, 25, 520-523.	1.3	25
9	Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish) Tj ETQq1 1 0.78	4314.rgBT 0.4	/Overlock 10
10	Olive-oil consumption and cancer risk. European Journal of Clinical Nutrition, 2003, 57, 191-191.	1.3	23
11	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, 181-190.e2.	1.1	23
12	The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Journal of Experimental and Clinical Cancer Research, 2009, 28, 97.	3.5	21
13	Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. International Urology and Nephrology, 2014, 46, 1531-1535.	0.6	21
14	Unilateral hand–foot syndrome: an extraordinary side effect of capecitabine. Cutaneous and Ocular Toxicology, 2010, 29, 140-142.	0.5	20
15	Haemostatic Changes; Plasma Levels of Alpha2-Antiplasmin-Plasmin Complex and Thrombin-Antithrombin III Complex in Female Breast Cancer. Tumori, 1998, 84, 364-367.	0.6	19
16	Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy. Cancer Management and Research, 2019, Volume 11, 8807-8815.	0.9	19
17	Primary Renal Lymphoma: Report of Four Cases. Oncology Research and Treatment, 2009, 32, 200-202.	0.8	18
18	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer, 2020, 148, 48-54.	0.9	18

#	Article	IF	CITATIONS
19	Imipenem - Cilastatin versus Sulbactam - Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients. Korean Journal of Internal Medicine, 1999, 14, 15-19.	0.7	16
20	A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin. American Journal of Gastroenterology, 2000, 95, 1093-1094.	0.2	15
21	Appendicular Metastasis From Pancreatic Adenocarcinoma. International Journal of Gastrointestinal Cancer, 2004, 34, 55-58.	0.4	15
22	Drug interaction between capecitabine and warfarin: a case report and review of the literature. International Journal of Clinical Pharmacology and Therapeutics, 2006, 44, 80-82.	0.3	14
23	Multiple Myeloma With Pleural Involvement. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 429-430.	0.6	13
24	Prostate Small Cell Carcinoma and Skin Metastases: A Rare Entity. Medical Principles and Practice, 2008, 17, 250-252.	1.1	12
25	Acute Interstitial Pneumopathy Associated with Docetaxel Hypersensitivity. Oncology Research and Treatment, 2004, 27, 563-565.	0.8	10
26	Primary Squamous Cell Carcinoma of the Stomach a Case Report. Tumori, 2005, 91, 440-442.	0.6	10
27	Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study. Medical Oncology, 2012, 29, 3608-3613.	1.2	10
28	Colon Adenocarcinoma and Solitary Tibia Metastasis: Rare Entity. Journal of Gastrointestinal Cancer, 2008, 39, 146-148.	0.6	9
29	Procalcitonin as a biomarker for infection-related mortality in cancer patients. Current Opinion in Supportive and Palliative Care, 2015, 9, 168-173.	0.5	9
30	Squamous cell carcinoma of the renal pelvis. Medical Oncology, 2009, 26, 103-104.	1.2	8
31	Concurrent Chemoradiotherapy with Vinorelbine plus Split-Dose Cisplatin may be an Option in Inoperable Stage III Non-Small Cell Lung Cancer: A Single-Center Experience. Medical Science Monitor, 2015, 21, 661-666.	0.5	8
32	Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8. Tumori, 2008, 94, 474-480.	0.6	7
33	Little dose, huge toxicity: profound hematological toxicity of intrathecal methotrexate. Leukemia and Lymphoma, 2009, 50, 282-283.	0.6	7
34	Signet-ring cell carcinoma of the colon with leptomeningeal involvement. Journal of Clinical Neuroscience, 2010, 17, 1051-1053.	0.8	7
35	Effectiveness of percutaneous metal stent placement in cholangiocarcinoma patients with midterm follow-up: Single center experience. European Journal of Radiology, 2012, 81, 1724-1727.	1.2	7
36	Perspectives and practical applications of medical oncologists on defensive medicine (SYSIPHUS) Tj ETQq0 0	0 rgBT /Over 1.2	lock 10 Tf 50 7

Medical Oncology, 2015, 32, 106.

#	Article	IF	CITATIONS
37	The Perspective of Non-oncologist Physicians on Patients with Metastatic Cancer and Palliative Care (ALONE Study): A Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Journal of Cancer Education, 2015, 30, 253-259.	0.6	7
38	MALTOMA Presenting With Thrombocytopenia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 321-322.	0.6	6
39	Tamoxifen-Induced Cirrhotic Process. Breast Journal, 2001, 7, 442-443.	0.4	5
40	Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors. Supportive Care in Cancer, 2013, 21, 1131-1135.	1.0	5
41	Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS Journal of Clinical Oncology, 2019, 37, 4037-4037.	0.8	5
42	Primary Extranodal Non-Hodgkin's Lymphoma: Clinicopathological Features, Survival and Treatment Outcome in Two Cancer Centers of Southern Turkey. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7207-7211.	0.5	5
43	Lack of Prognostic Significance of C-erbB-2 Expression in Low- and High- grade Astrocytomas. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1333-1337.	0.5	5
44	Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma,) Tj ETQq0 0 0 rgBT/C 2002-2003.	Overlock 10 2.0	) Tf 50 467 Td 4
45	Cost-Effectiveness of Chemotherapy in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 3750-3752.	0.8	4
46	Primary thyroid lymphoma: report of two cases. East African Medical Journal, 2004, 81, 378-80.	0.0	4
47	Prognostically Favorable Abdominal Breast Cancer Metastases with Stomach Involvement. Oncology Research and Treatment, 2005, 28, 270-272.	0.8	4
48	Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases. Molecular and Clinical Oncology, 2015, 3, 400-402.	0.4	4
49	Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?. Medical Oncology, 2015, 32, 476.	1.2	4
50	Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1123-1132.	0.4	4
51	Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients. Journal of Oncology, 2018, 2018, 1-9.	0.6	4
52	Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Journal of Cancer Education, 2020, 35, 69-75.	0.6	4
53	273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer. Annals of Oncology, 2020, 31, S348.	0.6	4
54	Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?. Medical Science Monitor, 2014, 20, 428-433.	0.5	4

#	Article	IF	CITATIONS
55	Malignant pleural mesothelioma: A single-center experience in Turkey. Medical Science Monitor, 2014, 20, 825-832.	0.5	4
56	Hodgkin′s disease in an elderly patient with B-Cell chronic lymphocytic leukemia. Indian Journal of Cancer, 2005, 42, 158.	0.2	4
57	Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8. Tumori, 2008, 94, 474-80.	0.6	4
58	Prevalence of hepatitis C, B and D markers in cancer patients in Turkey. European Journal of Clinical Microbiology and Infectious Diseases, 1994, 13, 38-40.	1.3	3
59	The correlation between <i>p53</i> tumor suppressor gene and proliferating cell nuclear antigen expressions in colorectal adenocarcinoma. Pathology International, 1995, 45, 973-974.	0.6	3
60	Acute Myeloid Leukemia 4 Years After Kaposi's Sarcoma in a Renal Transplant Recipient. Oncology Research and Treatment, 2004, 27, 163-165.	0.8	3
61	VBâ€CHEP chemotherapy regimen for aggressive nonâ€Hodgkin's lymphomas. European Journal of Haematology, 1998, 61, 261-265.	1.1	3
62	Successful Treatment of Aortic Rupture with Endovascular Stent Grafting in a Patient with Mantle Cell Lymphoma. Case Reports in Oncology, 2012, 5, 275-279.	0.3	3
63	A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study. OncoTargets and Therapy, 2018, Volume 11, 1223-1228.	1.0	3
64	P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey. Journal of Thoracic Oncology, 2019, 14, S558-S559.	0.5	3
65	Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: Baskent University experience Journal of Clinical Oncology, 2011, 29, e16001-e16001.	0.8	3
66	nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer. Breast Cancer Research and Treatment, 2022, 195, 55-64.	: 1.1	3
67	Adenocarcinoma of the Lung in a 32-Year-Old Man: Is It Worthwhile to Check for Lung Cancer in Young Adults?. Oncology Research and Treatment, 2002, 25, 64-64.	0.8	2
68	Treatment results in renal transplant recipients with non-Hodgkin's lymphoma. Transplantation Proceedings, 2003, 35, 1404-1407.	0.3	2
69	Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study. Medical Oncology, 2014, 31, 350.	1.2	2
70	Abstract PD1-11: nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer. , 2019, , .		2
71	Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas. European Journal of Cancer, 1998, 34, 759-760.	1.3	1
72	Gastric Hodgkin's disease presenting with radiological appearance of linitis plastica. American Journal of Gastroenterology, 1999, 94, 3661-3662.	0.2	1

#	Article	IF	CITATIONS
73	CA 15-3, Ceruloplasmin and tissue polypeptide specific antigen as a tumour marker panel in breast cancer. East African Medical Journal, 2009, 77, 291-4.	0.0	1
74	Hypertension Associated With Angiogoenesis Inhibitors: What Do Oncologists Really Do in Daily Routine? A Small Survey. Journal of Clinical Hypertension, 2011, 13, 863-863.	1.0	1
75	Weight Loss Despite Oral Glutamine Supplementation Predicts Poor Prognosis in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. Annals of Oncology, 2012, 23, ix520-ix521.	0.6	1
76	Does Fascin Expression in Diffuse Large B-Cell Lymphomas have a Clinical Impact in Patients Treated with Anthracyclin-Based Chemotherapy Plus Rituximab?. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2013, , 73-78.	0.1	1
77	Multifocal soft tissue Langerhans' cell histiocytosis treated with PET-CT based conformal radiotherapy. Japanese Journal of Radiology, 2015, 33, 603-606.	1.0	1
78	An old enemy not to be forgotten during PET CT scanning of cancer patients: tuberculosis. Wspolczesna Onkologia, 2016, 2, 188-191.	0.7	1
79	110P: Predictive and prognostic role of T-regulatory cells in resected non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S103-S104.	0.5	1
80	Hepatotoxicity and Hepatic Dysfunction. , 2010, , 267-278.		1
81	The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study Journal of Clinical Oncology, 2011, 29, e19598-e19598.	0.8	1
82	Outcomes of Turkish National Breast Cancer Registry Journal of Clinical Oncology, 2017, 35, e12517-e12517.	0.8	1
83	Intrapleural and intraperitoneal palliative treatment of malignant effusions with mitoxantrone. Anti-Cancer Drugs, 1993, 4, 98-99.	0.7	0
84	Gastric Hodgkin's Disease Presenting With Radiological Appearance of Linitis Plastica. American Journal of Gastroenterology, 1999, 94, 3661-3662.	0.2	0
85	Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma. Cancer, 2002, 94, 282-282.	2.0	0
86	Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer, 2002, 95, 2038-2039.	2.0	0
87	Metastatic Cerebellar Medulloblastoma in the Liver Mimicking a Complicated Cyst: Sonographic and MDCT Findings. American Journal of Roentgenology, 2004, 183, 1608-1610.	1.0	0
88	Controversy in Folinic Acid Administration After Fluorouracil. Journal of Clinical Oncology, 2005, 23, 3862-3862.	0.8	0
89	Timing and Patterns of Disease Progression Following Concurrent Radiochemotherapy in Patients with Unresectable Locally-Advanced Pancreas Cancer. Annals of Oncology, 2012, 23, ix238.	0.6	0
90	Outcomes of Aggressive Concurrent Chemotherapy in Septuagenarians with Stage IIIB Non-Small Cell Lung Carcinoma. Annals of Oncology, 2012, 23, ix392.	0.6	0

#	Article	IF	CITATIONS
91	Definitive Thoracic Chemoradiotherapy in Non-Small Cell Lung Cancer Patients with Solitary Brain Metastasis. Annals of Oncology, 2012, 23, ix424.	0.6	0
92	Role of Vitamin D3 in Prevention of Radiotherapy-Induced Epiphyseal Injury. Annals of Oncology, 2012, 23, ix526.	0.6	0
93	Does FDG-PET-CT based Re-Staging Influences Initial Management Decision and Clinical Outcome in Patients with locally advanced Pancreatic Carcinoma Planned to Undergo Chemoradiotherapy?. Annals of Oncology, 2012, 23, ix237.	0.6	0
94	Effect of Zoledronic Acid Used Concurrently with Radiation Therapy on Growth of Bone Epiphysesal Plaque. Annals of Oncology, 2012, 23, ix526.	0.6	0
95	Prognostic Role of T-Regulatory Cells in Completely Resected Early Stage Non-Small Cell Lung Carcinoma. Annals of Oncology, 2015, 26, i18.	0.6	0
96	P352 A puzzle for breast surgeons: type and timing of the surgery for metastatic breast cancer. Breast, 2015, 24, S148.	0.9	0
97	P1.17-02 Low Prognostic Nutritional Index Predicts Poor Survival in Stage IIIB Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. Journal of Thoracic Oncology, 2018, 13, S655.	0.5	Ο
98	Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. Journal of Oncology Pharmacy Practice, 2021, 27, 1623-1630.	0.5	0
99	Role of c-erbb2 expression in non-small cell lung cancer. Journal of Clinical Oncology, 2008, 26, 22044-22044.	0.8	Ο
100	Cisplatin combination regimen in the second-line treatment of non-small cell lung cancer Journal of Clinical Oncology, 2010, 28, e18136-e18136.	0.8	0
101	Oncologic Treatment of Non-Small Cell Lung Cancer Part A: Neoadjuvant Chemotherapy Options for Non-Small Cell Lung Carcinoma. , 2013, , 365-370.		0
102	Oncologic Treatment of Non-Small Cell Lung Cancer Part B: Adjuvant Chemotherapy for Resected Non-Small Cell Lung Carcinoma. , 2013, , 371-376.		0
103	Superior Vena Cava Syndrome: Experience at the Hacettepe Medical Center. Annals of Saudi Medicine, 1992, 12, 587-589.	0.5	Ο
104	Investigational tests and treatments performed in terminal-stage cancer patients in two weeks before death: Supportive care study group in Turkish Oncology Association Journal of Clinical Oncology, 2014, 32, e20503-e20503.	0.8	0
105	Scleroderma after 5-fluorouracil and folinic acid therapy in a patient with colon carcinoma. Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2014, 39, .	0.0	0
106	Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry Journal of Clinical Oncology, 2015, 33, e12656-e12656.	0.8	0
107	Can primary tumor localization predict the which patient will have benefit from addition of taxanes to platin-5-FU based regimens in metastatic gastric cancer. Multi center retrospective analysis from Turkey, Society of Turkish Oncology Group study Journal of Clinical Oncology, 2015, 33, e15030.e15030.	0.8	0
108	Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry Journal of Clinical Oncology, 2015, 33, e12653-e12653.	0.8	0

Ozgur Ozyilkan

#	Article	IF	CITATIONS
109	Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry Journal of Clinical Oncology, 2015, 33, e12657-e12657.	0.8	0
110	Turkish National Breast Cancer Registry Journal of Clinical Oncology, 2015, 33, e12654-e12654.	0.8	0
111	Evaluation of flare phenomena in advanced colorectal cancer after bevacizumab cessation in the well-responded cases Journal of Clinical Oncology, 2016, 34, e15019-e15019.	0.8	0
112	Flare Phenomenon in Advanced Colorectal Cancer: Cessation of Bevacizumab after Predefined Cycles of Therapy may not Affect Outcome UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2017, 27, 53-59.	0.1	0
113	Characteristics of Turkish colorectal cancer patients and bevacizumab preference Journal of Clinical Oncology, 2017, 35, e15055-e15055.	0.8	0
114	Clinicohistopathological features and treatment outcomes in testicular lymphomas: A single center experience Journal of Clinical Oncology, 2018, 36, e16533-e16533.	0.8	0
115	Nöroendokrin tümörlerin klinikohistopatolojik özellikleri ve tedavi sonuçları: tek merkez deneyimi. Cukurova Medical Journal, 2018, 43, 533-538.	0.1	0
116	Abstract P4-12-30: Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. , 2020, , .		0